Gene eRandomized Controlled Trial of the Gastrin Receptor Antagonist Netazepide in Patients with Barrett's Esophagus

A randomized, double-blind, placebo-controlled trial of netazepide (YF476) in patients with BE without dysplasia was performed. Gene expression before and after treatment with netazepide and with a placebo was measured with RNASeq Overall design: Gene expression of Barrett's esophogus of patients treated with netazapeptde 25 mg or placebo once daily for 12 weeks before and after treatment. aa.pla.t1 placebo arm, before treatment with placebo, n=9. ab.pla.t2 placebo arm, after treatment with placebo, n=9. ba.trt.t1 treatment arm, before treatment with netazapeptide, n=10. bb.trt.t12treatment arm, after treatment with treatment with netazapeptide, n=10.